anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Callout

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 96,741
Current window 68,251-68,280
Pages 3,225
Rows per page 30
Component: Calloutclear collectionreset all
18 30 60

Component

68,251-68,280 of 96,741

filter-aware
04
This slide serves as a critique of clinical trial design and reporting practices, specifically regarding the SONAR trial.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The Monster1 hit
05
The text highlights discrepancies in reported ESKD numbers between different sources and questions the statistical significance of the primary renal outcome.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The Monster1 hit
06
The slide uses data from the RADAR trial to challenge the validity of UACR as a reliable surrogate endpoint for kidney function.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
07
The text argues that the rapid reversal of UACR effects upon drug cessation indicates a transient hemodynamic impact rather than structural renal improvement.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
08
The slide argues that the drug Atrasentan acts as a 'band-aid' by masking symptoms via surrogate endpoints without providing long-term structural benefit.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
09
The slide uses Kaplan-Meier survival curves to illustrate the convergence of outcomes between placebo and Atrasentan groups.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
10
The slide provides a critical analysis of a standard medical metric, highlighting its inaccuracies and limitations in clinical practice.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
11
The slide functions as a critique of clinical trial data integrity, specifically focusing on the inclusion of serum creatinine doubling and the use of inulin as a gold standard.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
12
The slide uses bar charts to show baseline vs treatment effects on GFR, ERBF, EFF, and ERVR, suggesting these metrics are influenced by blood dilution.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
13
The slide uses a table to highlight discrepancies in mortality reporting between the 'Enrichment' group and the 'Double-Blind' groups.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
14
Includes references to clinical trial data and expert commentary regarding cardiovascular and renal side effects of atrasentan.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
15
The text explicitly alleges data tampering regarding Acute Kidney Injury (AKI) reporting in the SONAR study.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The StruggleLoop · Pattern Hunter1 hit
16
The slide highlights discrepancies in reported clinical trial data, specifically regarding ESKD progression and adverse event reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
17
The slide uses a table to highlight inconsistent reporting of Acute Kidney Injury (AKI) across different study groups and provides a narrative critique of cardiac failure reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
18
The slide uses Kaplan-Meier survival curves to illustrate the effects of Atrasentan on primary composite renal outcomes in different patient cohorts.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
19
The slide argues that the drug causes fluid retention and anemia, contradicting the trial's stated conclusions.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
20
The text argues that the omission of hematocrit data in the SONAR trial masks a hemodynamic effect that would undermine claims of renal improvement.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
21
The slide uses a callout box for trial results and follows with a critical analysis of anemia as a side effect.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
22
Includes extensive footnotes citing regulatory documents and investor call transcripts.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
23
Includes a table detailing orphan drug designation and marketing approval for Filspari (sparsentan).Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
24
This is a text-heavy research note page focusing on competitive critique and data skepticism.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
25
The slide critiques the visual representation of clinical trial data, specifically the 'time-distorting' nature of the x-axis in the provided graph.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
26
The slide highlights inconsistencies between SONAR study reports and FDA filings, suggesting data manipulation to favor the drug's safety profile.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
27
The slide uses a table of clinical trial results to illustrate a methodological critique of composite endpoints.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
28
The text focuses on statistical manipulation in clinical trial endpoints and discrepancies in patient count reporting between AFFINITY and ALIGN studies.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
29
The slide uses a 'villain critique' approach to undermine the credibility of the company's clinical trial reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
30
The slide uses a combination of text-based argument and visual data (charts) to expose potential manipulation of clinical trial reporting.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller Beat · The VictoryLoop · Cost Of Inaction1 hit
34
Includes detailed diagrams of disease pathophysiology and clinical trial design.Chinook Therapeutics Inc (KDNY) · Carson C. Block
Research note Short seller 1 hit
02
The slide sets up a 'before/after' or 'reality vs. representation' critique typical of short-seller research notes.Vivion Investments · Carson Block
Research note Short seller Beat · Expose Contradiction1 hit
03
Uses hyperbolic language ('gulags') and external citation (The Guardian) to frame the property negatively.Vivion Investments · Carson Block
Research note Short seller 1 hit